RecruitingNot ApplicableNCT03924791

Transforaminal Epidural Injection in Acute Sciatica


Sponsor

C.L.A.Vleggeert-Lankamp

Enrollment

142 participants

Start Date

Jun 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

Patients suffering from sciatica are treated conservatively for the first 8 weeks due to the favourable prognosis. This period is preferably extended up to 14-16 weeks after which patients may opt for surgery. However, patients may experience severe discomfort due to pain in the leg which can lead to decreased physical activity and socio-economic problems. An adequate therapy to alleviate symptoms during this period of 'wait-and-see' is lacking. In this study, patients will be randomized to treatment with transforaminal epidural injections or standard oral pain medication.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Diagnosed with sciatica by GP
  • NRS leg pain of 6 or more on a 10-point NRS scale
  • Minimum duration of symptoms of 3 weeks and maximum duration of 8 weeks

Exclusion Criteria7

  • Age under 18 years
  • Condition preventing to receive transforaminal epidural injection
  • Severe scoliosis
  • Transforaminal epidural injection received in 6 months before randomization date
  • Surgery for sciatica at the same level
  • Surgery for sciatica at another level within one year before inclusion
  • Pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLidocaine

In combination with dexamethasone or methylprednisolone acetate

DRUGMethylprednisolone Acetate

In combination with lidocaine

DRUGDexamethasone

In combination with lidocaine


Locations(2)

Spaarne Gasthuis

Haarlem, Netherlands

Spaarne Gasthuis

Hoofddorp, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03924791


Related Trials